All In Biotech

Investigational drug · Phase 3

Atezolizumab followed by Atezolizumab

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma.

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

299

Any phase or sponsor naming "Atezolizumab followed by Atezolizumab"

First trial start

2026

Aug 4, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Atezolizumab followed by Atezolizumab", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Small Cell Lung Cancer Extensive Stage
  • Small-cell Lung Cancer
  • Small Cell Carcinoma
  • Sclc
  • SCLC,Extensive Stage
  • Lung Cancer
  • Lung Cancer Metastatic
  • Lung Cancer Stage IV

Approved drugs for the same conditions: Small cell lung cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "Atezolizumab followed by Atezolizumab" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Small Cell Lung Cancer Extensive Stage

  • I-DXdDS-7300a, MK-2400Phase 317 trials

    Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma

  • IfebemtinibIN10018, BI853520Phase 311 trials

    InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer

  • QLC5508MHB088CPhase 39 trials

    Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma

  • GocatamigHPN328, MK-6070Phase 34 trials

    Merck & Co. · Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage, Small-Cell Lung Cancer

  • BL-M14D1Phase 32 trials

    SystImmune Inc. · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma

  • quaratusugene ozeplasmidREQORSAPhase 22 trials

    Genprex, Inc. · Carcinoma, Non-Small Cell Lung, Small Cell Lung Cancer Extensive Stage

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.